Immatics Biotechnologies GmbH
7 clinical trials · Sponsor
◉ Watch Immatics Biotechnologies GmbH
| Record | Firm | Date |
|---|---|---|
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor (NCT05359445) | Immatics Biotechnologies GmbH | 2022-05-19 |
Track Immatics Biotechnologies GmbH automatically
Every clearance here is in the API, with alerts when new ones post.